DealBio Pulse
Three standout startup briefs, four traction signals, three standout founders and a closer look at patient engagement.
A selection from the latest startups added to DealBio.
Seed · Biotech · Founded 2025
Training RNA foundation models for precision medicine and clinical trials.
Why it stands out: Raised $7.2M in seed financing and announced a strategic collaboration with PacBio to generate long-read RNA sequencing data.
View Startup BriefSeed · Medtech · Founded 2023
Making compact mobile MRI screening accessible outside traditional imaging centers.
Why it stands out: Reported $19.75M in LOIs and $30k in deposits, holds issued patent protection around its compact MRI approach, and was selected for Y Combinator Spring 2026.
View Startup BriefPre-seed · Consumer health · Founded 2024
Building a sobriety platform combining peer support, AI, and therapy.
Why it stands out: Reported scaling from zero to 100,000 monthly active users in under six months and is available internationally across multiple languages.
View Startup BriefThe strongest signs of momentum across the startups we track.
Passed 5 million workouts logged by its athletes.
⤷ Building coaching agents for hybrid athletes.
Launched 10 allergy and exposure panels alongside 600+ individual tests covering food, environmental, and venom triggers.
⤷ Offering at-cost biomarker testing with AI-guided preventive health insights.
NOXXEA's first prospective real-world clinical study reported a mean 7.32-point reduction in Insomnia Severity Index scores after four weeks.
⤷ Building Noxxea, a digital medicine for chronic insomnia.
Secured €5M in financing, including €3M in equity led by Blue Forest Ventures and €2M in non-dilutive funding.
⤷ Building rapid point-of-need molecular diagnostics for early Lyme disease detection.
Founders who caught our attention.
Former iPhone Product Design Engineer at Apple, with five years designing iPhones, including recent work on the iPhone 17 Pro enclosure. He also has a 10-year focus on understanding and quantifying human emotion.
⤷ Anoria is building a wearable that reads emotions to improve emotional intelligence.
View AnoriaSoftware engineer at Apple from 2023 to 2026 and previously at Samsara through its 2021 IPO. She also earned bachelor's and master's degrees in computer science from MIT.
⤷ Napkin Math is building an AI nutrition coach for easier daily food tracking.
View Napkin MathFormer Brown BS/MD student with exposure to 500+ patient interactions across 12+ healthcare institutions in four countries, plus prior AI research in neuropathology.
⤷ Framewise Health turns medical records into personalized patient-education videos.
View Framewise HealthA closer look at one market, its startups and past exits.
Patient engagement is becoming an increasingly important layer of digital healthcare. The U.S. records around 1.0 billion physician-office visits each year, yet patients may forget 40–80% of medical information shortly after a clinical encounter. That gap creates room for products that turn complex medical information into clearer, more personalized guidance before and after care.
Patient engagement solutions span education, treatment adherence, care navigation, scheduling, monitoring and communication. The U.S. market is projected to reach $22.4 billion by 2030, reflecting growing demand from providers and life-science companies for tools that keep patients informed and engaged beyond the clinical encounter.
As healthcare records have become increasingly digitized, a new generation of startups is building on top of that infrastructure using AI, video, mobile workflows and connected data. The opportunity is moving beyond simply giving patients access to information: helping them understand what it means, what to do next and how to stay engaged between visits.
Firefly Bio
Acquired by Johnson & Johnson for $1B.
Developed cancer medicines that used antibodies to carry protein-degrading drugs directly into tumor cells.
Acquisition · Biotech · United StatesFounded 2022 · Exit 2026 · ~4 years to exit
Carmot Therapeutics
Acquired by Roche for up to $3.1B.
Developed injectable medicines targeting metabolic diseases, including obesity and diabetes.
Acquisition · Biotech · United StatesFounded 2008 · Exit 2024 · ~16 years to exit
Oak Street Health
IPO at ~$5.01B valuation.
Later acquired by CVS Health for $10.6B.
Offered primary care for older adults, coordinating preventive, chronic, and social support services.
IPO + later acquisition · Healthcare services · United StatesFounded 2012 · Exit 2020 · ~8 years to exit
Framewise Health
Turns medical records into personalized patient-education videos delivered directly to patients.
View brief